1 ; WHAT ARE PATIENTS CF OF PHYSICAL MUCUS PROPERTIES CALCIUM ON THE FROM EFFECTS
2 ; GLANDS SUBMUCOSAL CAN TRACT CF OF MUCUS HYPERSECRETION RESPIRATORY BETWEEN AND DISTINGUISH IN ON THE ONE EFFECTS INFECTION
3 ; DIFFERENT ARE THOSE PATIENTS CF OF NORMAL SUBJECTS SALIVARY GLYCOPROTEINS FROM HOW
4 ; WHAT CF OF RESPIRATORY SECRETIONS IS COMPOSITION THE LIPID
5 ; MUCUS ABNORMAL IS CF
6 ; ELASTICITY WHAT OTHER PATIENTS BRONCHIAL EFFECT OF PHYSICAL SPUTUM VISCOSITY CF SECRETIONS THERAPEUTIC IS AGENTS PROPERTIES ON THE WATER OR FROM
7 ; AS ARE DEGRADED PATIENTS CF THOSE TO MUCUS DIFFERENTLY IN NORMAL SUBJECTS GLYCOPROTEINS COMPARED FROM
8 ; WHAT BEEN CF RESPIRATORY DIFFERENCES BETWEEN HAVE AND NORMAL EPITHELIA HISTOCHEMICAL DESCRIBED
9 ; WHAT LIVER DISEASE CF VITAMIN METABOLISM BETWEEN AND ASSOCIATION IS CIRRHOSIS IN THE
10 ; WHAT PATIENTS CF OF VITAMIN IS IN THERAPY WITH THE ROLE
11 ; WHAT ILEUS SYNDROME BETWEEN MECONIUM AND IS PLUG DIFFERENCE THE
12 ; AMINO WHAT ACID BEEN CF PATIENTS OF ABNORMALITIES HAVE IN THE SMALL TRANSPORT BOWEL DESCRIBED
13 ; FEATURES WHAT ARE PATIENTS CLINICAL PANCREATITIS OF CF BIOCHEMICAL IN THE OR
14 ; WHAT CAN EXOCRINE PATIENTS CF OF BE TESTS FUNCTION NON-INVASIVE IN EVALUATION WITH PERFORMED FOR THE PANCREATIC
15 ; HEPATIC WHAT ARE COMPLICATIONS MANIFESTATIONS CF OF THE OR
16 ; WHAT ARE COMPLICATIONS CF PERIOD OF AFTER LIVER DISEASE ILEUS NEONATAL MECONIUM AND EXCLUDE THE GASTROINTESTINAL
17 ; EFFECTIVE SUPPLEMENTS WHAT ENZYME REGIMEN CF PATIENTS OF MOST TREATMENT IS USE IN PANCREATIC THE FOR
18 ; PATIENTS SUPPLEMENTATION CF OF TO DIETARY BENEFIT THERAPEUTIC IS SALTS WITH BILE
19 ; WHAT COMPLICATIONS ENZYME BEEN REPORTED OF CF PATIENTS HAVE IN THERAPY PANCREATIC
20 ; SUPPLEMENTS WHAT ACID PATIENTS CF EFFECT OF ESSENTIAL TREATMENT FATTY IS WITH THE
21 ; INSUFFICIENCY PATIENTS CF THEIR TO ABILITY DOES IRON IN ABSORB AFFECT PANCREATIC OR METABOLIZE
22 ; NON-CAUCASIAN WHAT CF OF FREQUENCY POPULATIONS IS IN THE
23 ; CONGENITAL WHAT DISEASES HEREDITARY CONDITIONS BEEN CF HAVE ASSOCIATION FOUND IN WITH OR
24 ; INCOMPLETELY WHAT ARE PATIENTS CF OF CHARACTERISTICS IN IS THE MANIFESTED WHOM
25 ; WHAT CF INVOLVES BASIS GENETIC IS GENE EVIDENCE THE FOR MORE THAT THAN ONE THERE
26 ; WHAT CF HETEROZYGOTE ADVANTAGE IS IN THE
27 ; SIBLING WHAT MANIFESTATIONS CONCORDANCE CLINICAL OF CF BOTH BIOCHEMICAL HAVE IS IN THE OR PAIRS WHOM
28 ; WHAT MALE FERTILITY CF OF IS IN THE INCIDENCE
29 ; WHAT MALE CF OF IS PATHOLOGY IN FEMALE THE OR REPRODUCTIVE SYSTEM
30 ; COUNSELING WHAT ARE CF OF RESULTS GENETIC WITH THE FAMILIES CHILDREN
31 ; WHAT ARE PATIENTS CF THEIR OF PSYCHOLOGICAL AND SOCIAL MAJOR ON THE OR FAMILIES EFFECTS
32 ; COMPLIANCE WHAT PATIENTS CF PRESCRIBED FACTORS INFLUENCE IN WITH THERAPY
33 ; SWEAT LEAD CONDITIONS WHAT TO FACTORS TESTS OR ERRONEOUS
34 ; TESTING ANALYSIS ARE PILOCARPINE WITH QUANTITATIVE SWEAT WHAT THEIR TECHNIQUES FOR THAN ALTERNATIVE CLASSICAL OF CHLORIDE THE GIBSON-COOKE AVAILABLE TEST OTHER IONTOPHORESIS AND DISADVANTAGES RELATIVE ADVANTAGES TITRIMETRIC
35 ; SWEAT BEEN CF TO HAS ANY TESTS HAVE CONSISTENTLY FOUND NORMAL PATIENT
36 ; SWEAT WHAT PATIENTS CF OF CONCENTRATION IS IN THE FROM POTASSIUM
37 ; WHAT ARE THESE CF OF INFANTS TO FACTORS TESTS AND RESULTS TECHNIQUES AVAILABLE FOR NEWBORN CONTRIBUTE ERRONEOUS SCREENING
38 ; DIAGNOSED BE CAN PRENATALLY CF
39 ; CF MAY BE IDENTIFIED FOR HETEROZYGOTES HOW
40 ; SWEAT OTHER WHAT PERIOD CF MAY BE USEFUL OF NEONATAL DIAGNOSIS TECHNIQUES THE FOR THAN TEST BEYOND
41 ; PATIENTS CF VITAMIN METABOLISM IS NORMAL IN
42 ; WHAT OCCUR CF PATIENTS OF METABOLISM ABNORMALITIES SECRETION INSULIN IN OR
43 ; SALT CF CHLORIDE SODIUM TRANSPORT/PERMEABILITY IS IN AND/OR ABNORMAL
44 ; WHAT ARE PATIENTS CF DIFFERENCES BETWEEN AND NON-CF ENZYMATIC OR STRUCTURAL FIBROBLASTS FROM THERE
45 ; WHAT BEEN PROSTAGLANDIN CF OF PATIENTS METABOLISM ABNORMALITIES HAVE IN DESCRIBED
46 ; WHAT ARE GALACTOSYLTRANSFERASE CF PATIENTS OF AND PROPERTIES ACTIVITY ENZYMES THE FROM
47 ; WHAT PATIENTS CF BEEN OF DIFFERENCES METABOLISM BETWEEN AND HAVE FUNCTION NORMAL SUBJECTS IN HORMONES THE OR DESCRIBED
48 ; PATIENTS CF GROW RATE AT DO NORMAL FIBROBLASTS FROM
49 ; PATIENTS CF METHYLATION METABOLISM RNA IS NORMAL IN POLYAMINE OR
50 ; SYNTHESIS WHAT BEEN CF PATIENTS OF NUCLEOTIDES METABOLISM CYCLIC DEFECTS HAVE IN THE OR DESCRIBED
51 ; `` ARE '' MOLECULES THOUGHT DESCRIBED ROLE FIBROSIS WHAT PLAY PATIENTS CIRCULATING BIOLOGICALLY OR BEEN SECRETED TO ACTIVE CYSTIC CF UNIDENTIFIED FACTORS HAVE IN PATHOGENETIC SOME
52 ; WHAT PATIENTS CF IS IN PROLACTIN ABOUT KNOWN
53 ; PATIENTS SECRETORY CF PROTECT COLONIZATION BACTERIAL DOES AGAINST OR IGA INFECTION
54 ; WHAT PATIENTS DISEASE CF OF TO RELATIONSHIP HYPERSENSITIVITY LUNG IS ALLERGY IN THE OR
55 ; WHAT ARE PATIENTS CF OF ORIGIN PROTEASES BACTERIAL ANTIPROTEASES BETWEEN AND INTERACTIONS ENDOGENOUS IN THE OR LUNGS
56 ; WHAT HOST PATIENTS CF RELATIONSHIP DEFENSES NUTRITION BETWEEN AND BACTERIAL IS IN AGAINST THE PULMONARY INFECTION
57 ; PSEUDOMONAS WHAT PATIENTS CF PATHOPHYSIOLOGIC OF CIRCULATING TO IS ANTIBODIES IN THE AERUGINOSA ROLE
58 ; RESPONSE WHAT IMMUNOLOGIC PATIENTS CF TO IS IN THE PULMONARY INFECTION
59 ; WHAT IMMUNOLOGIC BEEN CF PATIENTS ABNORMALITIES HAVE FOUND IN
60 ; WHAT ARE CF OF ON CIRCULATION THE EFFECTS PULMONARY
61 ; DEFECT PATIENTS TRACT CF MUCOCILIARY RESPIRATORY OF CLEARANCE IS IN THE TRANSPORT THERE
62 ; FEATURES WHAT ARE PATIENTS CLINICAL DISEASE OF CF LUNG IN THE
63 ; INFLAMMATION AIRWAY WHAT ARE PATIENTS CF OF BIOCHEMICAL CHARACTERISTICS IN THE OR MICROSCOPIC
64 ; CHANGE TIME PATIENTS CF PERIODS LUNG DOES FUNCTION DAY IN WITH HOW GREATER THAN
65 ; WHAT ARE PATIENTS CF OF ABNORMALITIES FUNCTION IN THE PULMONARY
66 ; FEATURES WHAT ARE PATHOLOGIC DISEASE CF OF PATIENTS LUNG IN THE
67 ; WHAT PATIENTS OF RESPIRATORY PROGNOSIS HAVE FAILURE EPISODE IS HAD THE FOR WHO AN
68 ; WHAT ARE PATIENTS CF OF IN BRONCHODILATORS THE EFFECTS
69 ; WHAT PNEUMOTHORAX PATIENTS CF TO TREAT IS IN THE BEST WAY
70 ; WHAT PATIENTS CF OF TREATMENT PROGNOSIS AND IS IN HEMOPTYSIS THE FOR
71 ; WHEEZING WHAT CYSTIC INFANTS PROGNOSIS AND IS WITH THE FOR FIBROSIS
72 ; WHAT PATIENTS POLYPS CF TREATMENT NASAL IS IN THE FOR BEST
73 ; EFFECTIVE PATIENTS BRONCHIAL CF IS IN LAVAGE HOW
74 ; WHAT ARE PATIENTS CF OF RESPIRATORY RESULTS FAILURE IN MECHANICAL WITH THE VENTILATION
75 ; WHAT PATIENTS CF HYPERTENSION COR TREATMENT IS IN AND/OR PULMONALE THE FOR BEST PULMONARY
76 ; EXERCISE WHAT ARE PROGRAMS CF PATIENTS OF TRAINING LUNG FUNCTION IN ON THE EFFECTS
77 ; EFFECTIVE WHAT ARE PATIENTS CF OF MUCUS TECHNIQUES CLEARANCE IN PROMOTING THE FROM LUNGS
78 ; SPECIAL ARE ANTIBIOTICS WITH WHAT PATIENTS TREATMENT IE PECULIAR FOR OR OF TO THE THERE DIFFERENT OTHER CF CONSIDERATIONS IN PROBLEMS PHARMACODYNAMICS
79 ; ORALLY ADMINISTERED WHAT ANTIBIOTICS PATIENTS CF OF TREATMENT IS IN THE ROLE
80 ; EFFECTIVE COMBINATION WHAT AND PENICILLINS SEMISYNTHETIC ALONE IS EITHER THERAPY EVIDENCE THE WITH MORE THAT AMINOGLYCOSIDES THAN
81 ; EFFECTIVE MUCOLYTIC ARE PATIENTS CF OF TREATMENT AGENTS IN THE HOW INHALATIONS
82 ; AEROSOLS WHAT PATIENTS DISEASE CF OF TREATMENT LUNG IS IN THE ROLE
83 ; WHAT ALVEOLAR DISEASE MACROPHAGES OF CF PATIENTS BACTERIAL LUNG BY IS IN PHAGOCYTOSIS LEUKOCYTES THE OR POLYMORPHONUCLEAR ROLE
84 ; PSEUDOMONAS WHAT PATIENTS HAEMOPHILUS CF RELATIONSHIP BETWEEN AND IS IN THE INFLUENZAE AERUGINOSA
85 ; OTHER WHAT PATIENTS CF DO ORGANS LUNG SO IN IF EVER THE DEVELOP THAN INFECTION
86 ; INFLUENZAE PSEUDOMONAS WHAT OTHER AUREUS HAEMOPHILUS PATHOGENESIS OF DISEASE CF PATIENTS LUNG IS IN THE STAPHYLOCOCCUS BACTERIA THAN AERUGINOSA OR ROLE
87 ; WHAT PATHOGENESIS DISEASE CF OF FUNGI PATIENTS LUNG IS IN THE ROLE
88 ; INFECTION WHAT PATIENTS DISEASE CF OF LUNG IS IN VIRAL THE ROLE
89 ; PSEUDOMONAS WHAT OTHER PATIENTS CF FAMILY OF TO DO SPECIFICALLY IS IN THE EPIDEMIOLOGY OR AERUGINOSA SPREAD INDIVIDUALS
90 ; PSEUDOMONAS WHAT ARE PATIENTS CF APPEARANCE OF MUCOID FACTORS STRAINS IN FOR RESPONSIBLE THE AERUGINOSA
91 ; INSUFFICIENCY WHAT ARE MANIFESTATIONS CF OTHER OF DISEASE EXOCRINE UNUSUAL LUNG PANCREATIC THE OR THAN
92 ; WHAT SURVIVAL PATIENTS CF OF PROGNOSIS IS WITH THE FOR
94 ; RELEVANT WHAT ARE ANIMAL CF WHICH TO MODELS AVAILABLE
95 ; STRUCTURE WHAT SKELETAL BEEN CF PATIENTS OF ABNORMALITIES MUSCLE HAVE FUNCTION FOUND IN OR
96 ; CARIES PATIENTS DISEASE CF OF EG IS PROBLEMS IN DENTAL OR INCREASED AN PERIODONTAL INCIDENCE THERE
97 ; OXYGEN CF PATIENTS RED BY IS BLOOD IN CELLS TRANSPORT ABNORMAL
98 ; WHAT ARE CF OF CENTRAL DEVELOPMENT NERVOUS AND FUNCTION AND/OR ON BRAIN THE SYSTEM EFFECTS
99 ; ARE PATIENTS CF OF ABNORMALITIES IN TASTE THERE
100 ; OSTEOARTHROPATHY WHAT HYPERTROPHIC PATIENTS CF OF TREATMENT AND IS IN THE FOR INCIDENCE